A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis.

Trial Profile

A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2018

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Jan 2018 Results of post-hoc analysis assessing tofacitinib dose and plasma concentration as predictors of efficacy and identify covariates that determined efficacy in patients with UC, were published in the British Journal of Clinical Pharmacology.
    • 01 Nov 2017 Results of an integrated analysis assessing safety of Tofacitinib in NCT00787202, NCT01458574, NCT01458951, NCT01465763 and NCT01470612 (n=1240) presented at the 25th United European Gastroenterology Week
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top